Navigation Links
Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
Date:2/6/2008

Ranbaxy to Offer Both Suspension and Tablets

PRINCETON, N.J., Feb. 6 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Cefuroxime Axetil for Oral Suspension USP, 125 mg/5mL and 250 mg/5mL. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Ceftin(R) by GlaxoSmithKline. Total annual market sales for Cefuroxime Axetil Suspension were $28.7 million (IMS - MAT: December 2007).

Cefuroxime Axetil Suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the following conditions: Pharyngitis/Tonsillitis, Acute Bacterial Otitis Media and Impetigo.

"Ranbaxy is pleased to receive this approval for Cefuroxime Axetil Suspension that now allows us to offer both dosage forms for a product that is highly prescribed. We will offer Cefuroxime Axetil Suspension as a pleasant tasting liquid intended primarily for children that will ease in the acceptance and administration of this anti-infective. This product will further expand our product portfolio of affordable generic alternatives and will be launched immediately to all classes of trade," said Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

* Ceftin(R) is a registered trademark of GlaxoSmithKline

CONTACTS:

Charles M. Caprariello Edwige Buteau

Vice President, Corporate Communications RF Binder Partners Inc.

Ranbaxy Inc. (212) 994-7517

(609) 720-5615

Anuj Baveja

RF Binder Partners Inc.

(212) 994-7552


'/>"/>
SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
2. Ranbaxy Receives Tentative Approval For Valsartan Tablets
3. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
4. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
5. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
6. Shareholder Class Action Filed Against American Dental Partners, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Medicare Cuts in Bush Budget Shortsighted, Far Off the Mark in Protecting Seniors Long Term Care Needs, Sustaining Nursing Home Quality Gains
8. Hispanic Radio Listeners Nationwide to Support Life-Saving Efforts Against Childhood Cancer
9. Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia
10. National Health Care Alliance Gains New Members Against Aetnas New Anesthesia Policy
11. Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age ... Oxford University predict that 47 percent of all jobs in the United States may ... and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... , ... The California State University Institute for Palliative Care is ... in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic ... on Sept. 28 and 29, 2017, on the campus of California State University San ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that he ... of the Management Committee when IFN was originally formed in 2002 where he was ... development of the business plan. He became the first paid employee of IFN ...
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... ... for qualifying into the Senior International Elite division on February 12th. Ms. ... Around divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017  Directors from Pharma To Market Pty Ltd and ... forces, resulting in the founding of Pharma To Market Pte Ltd, ... Market are pleased to announce their expansion into Asia ... Singapore . The company are delighted to appoint Joelle ... Singapore based entity. Joelle brings with her ...
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has ... and Strategies - 2016" report to their offering. ... The latest research Urinary ... data and benchmarks in the global Urinary Incontinence market. The ... are the key drugs marketed for Urinary Incontinence and their clinical ...
Breaking Medicine Technology: